NCT05826535 2026-02-24Study of LYL314 in Aggressive Large B-Cell LymphomaLyell Immunopharma, Inc.Phase 1/2 Recruiting270 enrolled
NCT03328078 2025-06-05CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)Curis, Inc.Phase 1/2 Recruiting152 enrolled
NCT04104776 2025-05-15A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNovartisPhase 1/2 Recruiting275 enrolled
NCT06644443 2024-10-16BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple MyelomaShenzhen University General HospitalPhase 1/2 Recruiting10 enrolled
NCT04601584 2024-03-06GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALLAO GENERIUMPhase 1/2 Recruiting36 enrolled